A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Key facts

Sponsor

Jiangsu Gensciences lnc.

Principal Investigator

Renchi Yang

Hematology Hospital, Chinese Academy of Medical Sciences

Intervention

SS109(biological)

Enrollment

27 enrolled

Eligibility

18-65 years · MALE

Timeline

2022 – 2023

Study locations (10)

• Anhui Provincial Hospital, Hefei, Anhui, China
• Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
• Xiangya Hospital, Central South University, Changsha, Hunan, China
• Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
• Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China
• The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China
• The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
• Xi'an Central Hospital, Xi’an, Shanxi, China
• Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
• The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital factor VII deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07347249
  A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
  Hemab ApS
• RECRUITINGPHASE1NCT06349473
  A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
  Equilibra Bioscience LLC

See all trials for Congenital factor VII deficiency →